<DOC>
	<DOCNO>NCT01686633</DOCNO>
	<brief_summary>This Phase III , multicenter , randomize , double-blind , stratified , parallel-group study three active comparators subject moderate severe persistent asthma . The study consist run-in period 4 week , follow treatment period 12 week , follow contact period one week . The total duration study 17 week . 990 subject randomize one three treatment ( FF/VI Inhalation Powder 200/25 mcg daily evening ; FF/VI Inhalation Powder 100/25 mcg daily evening ; FF 100 Inhalation Powder daily even ) 12 week . In addition , subject supply albuterol/salbutamol inhalation aerosol Visit 1 use need acute asthma symptom throughout entire study . Subjects attend four on-treatment visit Weeks 2 , 4 , 8 , 12 ( Visits 4 7 ) .</brief_summary>
	<brief_title>An Efficacy Safety Study Fluticasone Furoate/Vilanterol ( FF/VI ) 200/25 Microgram ( mcg ) , FF/VI 100/25 mcg , FF 100 mcg Adults Adolescents With Persistent Asthma .</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<criteria>Subjects must give sign date ( write ) inform consent participate . Written informed consent must obtain subject 's current medication change result study participation Outpatient &gt; =12 year age Visit 1 diagnosis asthma , define National Institutes Health . Countries local restriction prohibit enrolment adolescent enroll subject &gt; =18 year age Male eligible female . Eligible female define nonchildbearing potential childbearing potential use acceptable method birth control consistently correctly . Best prebronchodilator FEV1 40 % 80 % predict normal value . Demonstrate &gt; =12 % &gt; =200 mL reversibility FEV1 within 10 40 minute follow 4 inhalation albuterol/salbutamol inhalation aerosol ( equivalent nebulized treatment albuterol/salbutamol solution ) document reversibility test within 6 month prior Visit 1 meeting measure reversibility . A spacer device may use test , require . If subject receive ICS least 12 week prior Visit 1 treatment 4 week immediately prior Visit 1 consist either two regimen ( b ) .a . ) A stable middose highdose ICS alone ( e.g. , &gt; =FP 250 mcg twice daily ) b . ) A stable dose middose ICS/LABA combination ( e.g. , FP/Salmeterol [ SALM ] 250/50 mcg twice daily ) equivalent combination via separate inhaler . Use ICS/LABA permit LABA day Visit 1 . Must able replace current SABA treatment albuterol/salbutamol aerosol inhaler Visit 1 use need , study . Subjects must able withhold albuterol/salbutamol least 6 hour prior study visit History lifethreatening asthma , define asthma episode require intubation and/or associate hypercapnia , respiratory arrest hypoxic seizure within last 5 year . Upper low respiratory tract , sinus , middle ear : resolve within 4 week Visit 1 lead change asthma management , opinion investigator , expect affect subject 's asthma status subject 's ability participate study . Any asthma exacerbation require oral corticosteroid within 12 week prior Visit 1 , result overnight hospitalization require additional treatment asthma within 6 month prior Visit 1 . A subject must current evidence atelectasis ( segmental large ) , bronchopulmonary dysplasia , chronic obstructive pulmonary disease , Or evidence concurrent respiratory disease asthma A subject must clinically significant , uncontrolled condition disease state , opinion investigator , would put safety subject risk study participation would confound interpretation efficacy result condition/disease exacerbate study Chronic stable hepatitis B C acceptable provide screen alanine transaminase ( ALT ) &lt; 2x upper limit normal ( ULN ) otherwise meet entry criterion . Chronic coinfection hepatitis B hepatitis C eligible Clinical visual evidence candidiasis Visit 1 Use investigational drug within 30 day prior Visit 1 within five halflives ( tÂ½ ) , whichever long two . Allergies drug milk protein : adverse reaction , beta2agonist , sympathomimetic drug , intranasal , inhale , systemic corticosteroid therapy know suspected sensitivity constituent NDPI , history severe milk protein allergy Administration medication would significantly affect course asthma , interact study drug Use immunosuppressive medication study . Use potent CYP3A4 inhibitor within 4 week Visit 1 . A subject his/her parent legal guardian infirmity , disability , disease , reside geographical location seem likely , opinion Investigator , impair compliance aspect study protocol , include visit schedule , completion daily diary . Current smoker smoke history 10 packyears ( 20 cigarettes/day 10 year ) . A subject may use inhale tobacco product within past 3 month ( i.e. , cigarette , cigar , pipe tobacco ) . If subject immediate family member participate investigator , subinvestigator , study coordinator , employee participate investigator . Subject previously randomize treatment FF/VI FF another Phase III study Subjects work night shift week prior Visit 1 study period . Adolescents ward state government</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>asthma</keyword>
	<keyword>pharmacogenetics</keyword>
	<keyword>adult</keyword>
	<keyword>vilanterol</keyword>
	<keyword>adolescent</keyword>
	<keyword>fluticasone furoate</keyword>
</DOC>